Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
The U.S. FDA rejection of an MDMA-based drug from Lykos Therapeutics for PTSD in August 2024 has not dimmed hopes that other psychedelic-oriented therapies can gain approval, according to the CEO of ...
Languages: English That has some policy experts confused about the FDA's ability to implement efficient recalls and protect Americans from foodborne illness or public health hazards. More ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help with treatment-resistant depression. Brandi Martin ...
The news comes less than two weeks after J&J secured FDA monotherapy approval for its esketamine nasal spray Spravato in the same indication. GH Research’s lead molecule, an inhaled 5-MeO-DMT ...
Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help with treatment-resistant depression. Brandi Martin, a nurse practitioner at NuVista, holds the device used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results